BioSapien

ApplicationUAEFounded 2018· One of 462 Application companies tracked by AMPulse

BioSapien, founded in 2018, pioneers minimally invasive drug delivery platforms with its signature MediChip™ technology, utilizing 3D printing to deliver targeted chemotherapy directly to tumor sites to minimize side effects.

CEO / Founder: Khatija Ali
Team Size: 11-50
Stage: Active
Total Funding: $10.6M
Latest Round: Pre-Series A
Key Investors: Global Ventures, Dara Holdings, RebelBio/IndieBio, Globivest, JPIN, SOSV, Hikma Ventures, Golden Gate Ventures

Technology & Products

Key Products

MediChip™: A 3D-printed, slow-release, biocompatible implantable patch designed to deliver targeted chemotherapy directly to tumor sites, minimizing side effects and enhancing treatment efficacy.

Technological Advantage

Ability to minimize systemic side effects and enhance treatment precision through targeted drug delivery.

Differentiation

Value Proposition

Targeted delivery of chemotherapy directly to tumors, minimizing side effects and enhancing treatment efficacy.

How They Differentiate

BioSapien differentiates itself through its focus on 3D-printed chemotherapy delivery via its MediChip™ technology, enabling targeted treatment directly to tumors, minimizing side effects, and enhancing treatment efficacy, unlike competitors who concentrate on diagnostics or genomics.

Market & Competition

Target Customers

Cancer patients seeking reduced systemic side effects from chemotherapy.

Industry Verticals

Biotech, Healthcare, Oncology

Competitors

PanTher Therapeutics, scPharmaceuticals, Vaxxas, Valeritas

Growth & Milestones

Growth Metrics

Received regulatory approval and advancing to Phase I clinical trials in Abu Dhabi (June 2026), with a goal to treat 1 million patients by 2035

Major Milestones

Global patent issuance for MediChip, Accepted into HUB71 Cohort 13, Received regulatory approval to advance to Phase I clinical trials in Abu Dhabi for MediChip™ (June 2026), Nominated for "Best Startup" at the 20th Prix Galien USA Awards (announced August 14, 2026)

Notable Customers

IROS

https://biosapien.com

Why this company matters

AMPulse analysis, not a company disclosure

BioSapien occupies a niche at the intersection of additive manufacturing and oncology, developing a 3D-printed drug delivery platform that targets chemotherapy directly to tumors. Founded in 2018 and based in the UAE, the company aims to reduce the debilitating systemic side effects of conventional chemotherapy by localizing treatment at the source.

The core product, MediChip, is a biocompatible, slow-release implantable patch produced via polymer additive manufacturing. The chip is designed to be placed at a tumor site during a minimally invasive procedure, releasing chemotherapy agents over a controlled period. This approach contrasts with systemic infusion or oral chemotherapy, which exposes the entire body to toxic drugs.

BioSapien targets cancer patients and oncology providers seeking alternatives to systemic chemotherapy. The company has been accepted into the Hub71 ecosystem in Abu Dhabi and counts IROS as a named customer. It is preparing for human clinical trials, with a stated goal of treating one million patients by 2035.

The company holds a European patent for the MediChip platform and additional patents related to biovessels and drug-eluting surgical articles. Competitors include PanTher Therapeutics and scPharmaceuticals, though BioSapien differentiates by using 3D printing to create a customizable, implantable delivery vehicle. Key investors include Global Ventures, SOSV, and Hikma Ventures. The primary open question is whether the MediChip can demonstrate safety and efficacy in human trials, which will determine its path to regulatory approval and commercial adoption.